CD19 and neoplasm: While all tumor relapsed mice (4/4) treated with CD19 redirected T cells (2nd Gen) died within 21 days after second-line treatment, 2/5 mice treated with CD19-specific CAR/CCR T cells were still alive at day 63 (Figures 4B–4D).